GMP-conformant on-site manufacturing of a CD133⁺ stem cell product for cardiovascular regeneration

详细信息    查看全文

• 作者：Anna Skorska ; Paula Müller ; Ralf Gaebel ; Jana Große…
• 关键词：Cardiovascular regeneration ; Adult hematopoietic stem cells ; Prodigy ; Good Manufacturing Practice (GMP) ; Clinical translation ; Advanced therapy medicinal product (ATMP) ; CD133+ cells ; Stem cell transplantation
• 刊名：Stem Cell Research & Therapy
• 出版年：2017
• 出版时间：December 2017
• 年：2017
• 卷：8
• 期：1
• 全文大小：1647KB
• 刊物主题：Stem Cells; Cell Biology;
• 出版者：BioMed Central
• ISSN：1757-6512
• 卷排序：8

文摘

BackgroundCD133+ stem cells represent a promising subpopulation for innovative cell-based therapies in cardiovascular regeneration. Several clinical trials have shown remarkable beneficial effects following their intramyocardial transplantation. Yet, the purification of CD133+ stem cells is typically performed in centralized clean room facilities using semi-automatic manufacturing processes based on magnetic cell sorting (MACS®). However, this requires time-consuming and cost-intensive logistics.